155 related articles for article (PubMed ID: 21321422)
21. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts.
Stark A; Lu M; Mackowiak P; Linden M
Breast J; 2005; 11(3):183-7. PubMed ID: 15871703
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients.
Lüftner D; Jung A; Schmid P; Geppert R; Kienle E; Wernecke KD; Possinger K;
Breast Cancer Res Treat; 2003 Aug; 80(3):245-55. PubMed ID: 14503797
[TBL] [Abstract][Full Text] [Related]
23. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody.
Witters LM; Kumar R; Chinchilli VM; Lipton A
Breast Cancer Res Treat; 1997 Jan; 42(1):1-5. PubMed ID: 9116313
[TBL] [Abstract][Full Text] [Related]
24. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).
Corte MD; Rodil JA; Vázquez J; García L; Rodríguez JC; Bongera M; Fernández JC; González LO; Lamelas ML; Allende M; García-Muñiz JL; Fueyo A; Vizoso FJ
J Cancer Res Clin Oncol; 2005 Nov; 131(11):701-14. PubMed ID: 16075281
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K
Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354
[TBL] [Abstract][Full Text] [Related]
28. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
[TBL] [Abstract][Full Text] [Related]
29. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
30. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
31. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
Archer SG; Eliopoulos A; Spandidos D; Barnes D; Ellis IO; Blamey RW; Nicholson RI; Robertson JF
Br J Cancer; 1995 Nov; 72(5):1259-66. PubMed ID: 7577479
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
33. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
34. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
35. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
Ali SM; Leitzel K; Chinchilli VM; Engle L; Demers L; Harvey HA; Carney W; Allard JW; Lipton A
Clin Chem; 2002 Aug; 48(8):1314-20. PubMed ID: 12142389
[TBL] [Abstract][Full Text] [Related]
36. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
Konecny GE; Meng YG; Untch M; Wang HJ; Bauerfeind I; Epstein M; Stieber P; Vernes JM; Gutierrez J; Hong K; Beryt M; Hepp H; Slamon DJ; Pegram MD
Clin Cancer Res; 2004 Mar; 10(5):1706-16. PubMed ID: 15014023
[TBL] [Abstract][Full Text] [Related]
37. Expression of HER-2/NEU oncoprotein in familial and non-familial breast cancer.
Tsai KB; Hou MF; Lin HJ; Chai CY; Liu CS; Huang TJ
Kaohsiung J Med Sci; 2001 Feb; 17(2):64-76. PubMed ID: 11416960
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
39. Discordant results obtained for different methods of HER-2/neu testing in breast cancer--a question of standardization, automation and timing.
Luftner D; Henschke P; Kafka A; Anagnostopoulos I; Wiechen K; Geppert R; Stein H; Wernecke KD; Kreienberg R; Possinger K
Int J Biol Markers; 2004; 19(1):1-13. PubMed ID: 15077921
[TBL] [Abstract][Full Text] [Related]
40. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.
Ross JS; Fletcher JA; Linette GP; Stec J; Clark E; Ayers M; Symmans WF; Pusztai L; Bloom KJ
Oncologist; 2003; 8(4):307-25. PubMed ID: 12897328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
